Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients

Dyslipidemias Clinical Trial

— RACHEL  

Official title:

Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00931320
• Other study ID #: NIS-CKR-DUM-2009/3
• Status: Completed
• Phase: N/A
• First received: June 30, 2009
• Last updated: October 23, 2009
• Start date: July 2009
• Est. completion date: September 2009

Study information

• Verified date: October 2009
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

An observational, non-interventional, multi-centre study to provide further information on the ratio of LDL-C to HDL-C improvement after statin treatment in Korean patients group.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3000
• Est. completion date: September 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects who are taking lipid-lowering medication after diagnosed as dyslipidaemia

• Subjects who have at least made 1 visit to the outpatient clinic within previous 6 months

• Subjects who have records of both LDL-C and HDL-C before & after statin treatment (at least four weeks after statin taking)

Exclusion Criteria:

• Subjects who are unwilling or unable to provide their examination and lab result of medical chart.

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Dyslipidemias

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate current LDL/HDL ratio in Korean patients (between baseline & after treatment)		After Treatment : at least 4 weeks before statin taking /Baseline : no limitation.	No
Secondary	Evaluate difference of LDL/HDL ratio among different statins & dosages (between baseline & after treatment)		After Treatment : at least 4 weeks before statin taking / Baseline : no limitation.	No